# Prime Medicine (PRME) — Analyst Forecast

PRME · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/prme/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 3 | 0 | 13 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $7.00 | $8.00 | $9.00 | 3 |

Last price $3.61 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 25, 2026 | Chardan Capital | Maintained | Buy | $7.00 |
| Aug 25, 2026 | Chardan Capital | Maintained | Buy | $7.00 |
| Aug 19, 2026 | BMO Capital | Initiated Coverage | Outperform | $9.00 |
| Aug 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $8.00 |
| Jun 29, 2026 | HC Wainwright & Co. | Upgraded | Neutral → Buy | $8.00 |
| Mar 12, 2026 | Oppenheimer | Initiated Coverage | Outperform | $11.00 |
| Dec 23, 2025 | LifeSci Capital | Initiated Coverage | Outperform | $6.00 |
| Nov 11, 2025 | Citigroup | Maintained | Neutral | $4.25 |
| Nov 10, 2025 | Chardan Capital | Maintained | Buy | $9.00 |
| Aug 8, 2025 | Chardan Capital | Maintained | Buy | $10.00 |
| May 27, 2025 | Citigroup | Downgraded | Buy → Neutral | $1.50 |
| May 20, 2025 | HC Wainwright & Co. | Downgraded | Buy → Neutral | — |
| May 20, 2025 | JP Morgan | Downgraded | Overweight → Neutral | — |
| May 20, 2025 | JMP Securities | Maintained | Market Outperform | $6.00 |
| May 19, 2025 | Chardan Capital | Maintained | Buy | $12.00 |
| Mar 20, 2025 | Chardan Capital | Maintained | Buy | $16.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| Mar 4, 2025 | Citizens Capital Markets | Maintained | Market Outperform | $10.00 |
| Mar 3, 2025 | Chardan Capital | Maintained | Buy | $15.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Maintained | Buy | $10.00 |

## Frequently Asked Questions

### What is the price target for PRME stock?

The average 12-month analyst price target for Prime Medicine (PRME) is $8.00, with a high estimate of $9.00 and a low of $7.00, across 3 analysts.

### Is PRME a buy, sell, or hold?

Analysts covering Prime Medicine currently average a Buy rating: 10 buy, 3 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for PRME?

The average price target of $8.00 implies 121.61% upside from the last price of $3.61.

### What is the latest analyst rating on PRME?

On Sep 25, 2026, Chardan Capital maintained Prime Medicine at Buy with a price target of $7.00.

## Similar Stocks

- [BEAM](https://www.lighthorse.io/tickers/beam) — Beam Therapeutics Inc. - Common Stock
- [CRSP](https://www.lighthorse.io/tickers/crsp) — CRISPR Therapeutics AG - Common Shares

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).